|Day Low/High||0.00 / 0.00|
|52 Wk Low/High||0.51 / 2.93|
Study RXI-109-1501 is evaluating the safety and clinical activity of RXI-109 to prevent the progression of retinal scarring, a harmful component of numerous retinal diseases
RXI-231 is in development as a cosmetic ingredient that may improve the appearance of uneven skin tone and pigmentation
Forum brings together leading family offices, foundations and impact investors seeking impact investment, grant-giving, and philanthropy opportunities within health and life sciences
RXI-109 is a self-delivering RNAi compound (sd-rxRNA) in development to reduce dermal and ocular fibrosis
Focusing on Advances in Immuno-Oncology
19th Annual BIO CEO & Investor Conference and 2nd Annual Disruptive Growth & Healthcare Conference
These under-$10 stocks are within range of triggering breakout trades.
Stocks with insider trader activity include RXII, MA and SWN
Trade-Ideas LLC identified RXi Pharmaceuticals (RXII) as a strong on high relative volume candidate
Upgrades: CEB, DAC, FARM, GIG, JOEZ, LGND, QDEL, RGC, RLOC, VCO, WSH Downgrades: AWRE, BNNY, CALX, ETR, GTS, HUN, ICE, NTT, PLOW, RDY Initiations: RXII Read on to get TheStreet Quant Ratings' detailed report:
RXi Pharmaceuticals Corporation (OTC: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies,...